The Claim
In aged female 3xTg mice, 7 days of istradefylline treatment is associated with a 45% increase in cortical occludin and a 30% increase in ZO-1 protein levels, restoring tight junction protein expression to levels comparable to those in healthy aged C57BL/6 mice.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In aged female mice with Alzheimer’s-like pathology, 7 days of istradefylline treatment increased levels of two proteins, occludin and ZO-1, in the brain’s blood vessels to match levels seen in healthy aged mice.
See the scientific wording
In aged female 3xTg mice, 7 days of istradefylline treatment was associated with a 45% increase in cortical occludin and a 30% increase in ZO-1 protein levels, restoring tight junction protein expression to levels comparable to healthy aged C57BL/6 mice, suggesting that A2A receptor blockade may improve blood-brain barrier integrity in this Alzheimer’s model.
Blocking a specific receptor in the brain reduces a harmful enzyme that interferes with blood vessel function, which in turn allows the brain's protective barrier to rebuild its sealing proteins and stop leaks.
What the research says
1 studyIn older mice with Alzheimer’s-like brain changes, a drug called istradefylline helped fix the brain’s protective barrier by increasing two key sealing proteins, bringing them back to levels seen in healthy mice.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.